Tuesday, September 16, 2025

Phage Therapy’s Rising Demand: Cytophage at the Forefront with Dr. Steven Theriault

FULL DISCLOSURE: This is sponsored content for Cytophage Technologies.

In this interview, Dr. Steven Theriault, CEO of Cytophage Technologies Ltd. (TSXV:CYTO), presents phage therapy as a potentially revolutionary biotech solution. He illustrates its efficacy by citing a successful treatment of a severe infection in Ottawa, underscoring the increasing demand for alternative treatments to combat antibiotic resistance.

Dr. Theriault outlines Cytophage’s expansion strategy, focusing on South Asia with a new product launch in Bangladesh and partnerships with major poultry integrators. He also touches on the development of phage-based vaccines and the company’s focus on both animal and human applications.

Looking ahead, Dr. Theriault highlights Cytophage’s goals: revenue generation, advancement of human clinical trials, and formation of strategic partnerships. These reflect the company’s ambition to capitalize on the growing interest in phage therapy.


FULL DISCLOSURE: Cytophage Technologies is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cytophage Technologies. The author has been compensated to cover Cytophage Technologies on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

New Found Gold: The Strategic Maritime Resources Purchase

Amex Exploration: Revised Perron PEA Has INSANE Economics

Aris Mining: The Multi Billion Dollar Soto Norte PFS

Recommended

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Goliath Resources Hits 18.58 g/t Gold Over 5.00 Metres At Surebet

Related News

Cytophage Sees Its Bacteriophages Used As Treatment In Canada Under Single Subject Clinical Trial

For the first time in Canadian history, bacteriophage therapy is slated to be utilized to...
Friday, March 1, 2024, 10:14:56 AM

Cytophage Enters Letter Of Intent With Major Singapore-Based Agrifood Company

Cytophage Technologies (TSXV: CYTO) is focusing its efforts on expanding the commercialization of its phage...
Friday, June 21, 2024, 08:45:08 AM

Cytophage Reports Early Success In Single Subject Clinical Trial

Cytophage Technologies (TSXV: CYTO) has seen early success in a recently completed human trial conducted...
Tuesday, April 2, 2024, 09:05:42 AM

The Solution To Antibiotic Resistance – With Cytophage CEO Dr Steven Theriault

FULL DISCLOSURE: This is sponsored content for Cytophage Technologies. In this interview, Dr. Steven Theriault...

Thursday, February 22, 2024, 01:30:00 PM

Cytophage To Focus On Commercialization Efforts In 2024

Cytophage Technologies (TSXV: CYTO) has filed its fiscal 2023 results, providing a recap on a...
Tuesday, April 30, 2024, 10:13:02 AM